Atezolizumab with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer [ID1522]
In development [GID-TA10433] Expected publication date: TBC
Search results
905 results
-
-
Lisocabtagene maraleucel for treating large B-cell lymphoma after at least 2 therapies ID1444
In development [GID-TA10477] Expected publication date: TBC
-
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]
In development [GID-TA10370] Expected publication date: TBC
-
Talazoparib for treating BRCA 1 or 2 mutated advanced breast cancer after prior chemotherapy (ID1342)
In development [GID-TA10366] Expected publication date: TBC
-
Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179
In development [GID-TA10450] Expected publication date: 14 July 2021
-
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]
In development [GID-TA10577] Expected publication date: 21 April 2021
-
Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]
In development [GID-TA10495] Expected publication date: 19 May 2021
-
Galcanezumab for preventing cluster headache [ID1212]
In development [GID-TA10425] Expected publication date: 24 February 2021
-
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488
In development [GID-TA10432] Expected publication date: 14 October 2020
-
Entrectinib for treating ROS1-positive locally advanced or metastatic non-small-cell lung cancer [ID1541]
In development [GID-TA10415] Expected publication date: TBC
-
Zynteglo for treating transfusion-dependent beta-thalassaemia ID968
In development [GID-TA10334] Expected publication date: 15 July 2020
-
Entrectinib for treating NTRK fusion-positive solid tumours ID1512
In development [GID-TA10414] Expected publication date: TBC
-
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]
In development [GID-TA10122] Expected publication date: TBC
-
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]
In development [GID-TA10489] Expected publication date: 23 September 2020
-
Atezolizumab with gemcitabine and carboplatin for treating metastatic urothelial bladder cancer [ID1206]
In development [GID-TA10202] Expected publication date: TBC
-
Ivosidenib for treating relapsed or refractory acute myeloid leukaemia ID1548
In development [GID-TA10416] Expected publication date: 28 April 2021
-
Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]
In development [GID-TA10429] Expected publication date: TBC
-
Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]
In development [GID-TA10399] Expected publication date: TBC
-
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]
In development [GID-TA10363] Expected publication date: TBC
-
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]
In development [GID-TA10539] Expected publication date: TBC
-
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
In development [GID-TA10221] Expected publication date: TBC
-
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed [ID2710]
In development [GID-TA10586] Expected publication date: TBC
-
Fenfluramine for treating Dravet syndrome [ID1109]
In development [GID-TA10373] Expected publication date: TBC
-
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) ID1585
In development [GID-TA10538] Expected publication date: 12 August 2020
-
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
In development [GID-TA10024] Expected publication date: 28 June 2017
-
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]
In development [GID-TA10254] Expected publication date: TBC
-
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]
In development [GID-TA10046] Expected publication date: 22 November 2017
-
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
In development [GID-TA10623] Expected publication date: TBC
-
Avelumab for maintenance treatment of advanced urothelial cancer after platinum-based chemotherapy [ID3735]
In development [GID-TA10624] Expected publication date: TBC
-
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID1504]
In development [GID-TA10400] Expected publication date: TBC
-
Atezolizumab with nab-paclitaxel for neoadjuvant treatment of early triple negative breast cancer [ID1574]
In development [GID-TA10531] Expected publication date: 15 December 2021
-
Acalabrutinib for untreated and treated chronic lymphocytic leukaemia [ID1613]
In development [GID-TA10532] Expected publication date: TBC
-
Lenvatinib with everolimus or pembrolizumab for untreated advanced renal cell carcinoma [ID3760]
In development [GID-TA10629] Expected publication date: TBC
-
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations [ID3761]
In development [GID-TA10630] Expected publication date: TBC
-
Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]
In development [GID-TA10632] Expected publication date: TBC
-
Durvalumab for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations and high PD-L1 expression [ID3762]
In development [GID-TA10633] Expected publication date: TBC
-
Midostaurin for treating advanced systemic mastocytosis ID1573
In development [GID-TA10503] Expected publication date: 11 November 2020
-
Nivolumab for previously treated squamous non-small-cell lung cancer (CDF Review TA483) [ID1559]
In development [GID-TA10516] Expected publication date: 06 May 2020
-
Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]
In development [GID-TA10513] Expected publication date: 06 May 2020
-
Naldemedine for treating opioid-induced constipation ID1189
In development [GID-TA10291] Expected publication date: 05 June 2020
-
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia [ID2708]
In development [GID-TA10588] Expected publication date: 24 March 2021
-
Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable ID1564
In development [GID-TA10478] Expected publication date: 10 February 2021
-
Idebenone for treating Duchenne muscular dystrophy ID1092
In development [GID-TA10310] Expected publication date: TBC
-
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant [ID1508]
In development [GID-TA10421] Expected publication date: TBC
-
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]
In development [GID-TA10259] Expected publication date: TBC
-
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure [ID3754]
In development [GID-TA10621] Expected publication date: TBC
-
Durvalumab (Imfinzi) + Tremelimumab + standard chemotherapy for non-small cell lung cancer (NSCLC) lacking activating EGFR mutations and ALK fusions ID1538
In development [GID-TA10422] Expected publication date: TBC
-
Melanoma (metastatic) - talimogene laherparepvec [ID508]
In development [GID-TAG509] Expected publication date: 28 September 2016
-
KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494
In development [GID-TA10424] Expected publication date: TBC
-
Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]
In development [GID-TA10168] Expected publication date: TBC